8-K

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT


                        Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934


      Date of Report (Date of earliest event reported):  January 10, 2006


                                HUMAN BIOSYSTEMS
             (Exact name of registrant as specified in its charter)

                                   000-28413
                            (Commission File Number)

           California                                      77-0481056
 (State or other jurisdiction             (I.R.S. Employer Identification No.)
                       of incorporation or organization)

                    1127 Harker Avenue, Palo Alto, CA 94301
          (Address of Principal Executive Offices Including Zip Code)

Registrant's telephone number, including area code: (650) 323-0943

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (See General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))
========================================================================
Item 8.01 Other Events

On July 19, 2005, Human BioSystems ("HBS") issued an Exchange Offer to its Reg S
stockholders in Germany to exchange one share of HBS common stock for each of
the shares of Reg S Stock outstanding before or upon the de-listing date when
the Reg S Stock is no longer tradable.  This Exchange Offer is only applicable
to HBS Reg S stockholders in Germany.

The Exchange Offer was scheduled to expire on December 19, 2005.  However, on
January 10, 2006, Human BioSystems issued a Press Release stating that because
of delays due to the early confusion regarding procedures and its subsequent
changes to those procedures, Human BioSystems is extending the deadline from
December 29, 2005 to January 31, 2006.  See the attached copy of the Press
Release.

Item 9.01 Financial Statements and Exhibits

(a)	Financial Statements of Business Acquired: Not Applicable
(b)	Pro Forma Financial Information: Not Applicable
(c)	Exhibits: The following exhibits are included as part of this report:

Exhibit No.	 Description
- --------------  ---------------
99.1		Press Release, dated January 10, 2006


SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated: January 23, 2006


HUMAN BIOSYSTEMS


By:	/s/ Harry Masuda
        -----------------
         Harry Masuda
	 CEO

EX-99.1

Exhibit 99.1
                                  [LETTERHEAD]
                                Human BioSystems


                                January 10, 2006



Re:Human BioSystems - Extension of Common Stock Exchange Offer

Dear Human BioSystems Reg S Shareholder:

Human BioSystems issued a press release on July 19, 2005 regarding the exchange
of Reg S common stock, trading under WKN#164580 for shares of New Stock. On
August 8, 2005, a subsequent press release was issued regarding changes to the
procedures for returning the Reg S shares.

The exchange offer was scheduled to expire on December 29, 2005. However,
because of delays due to the early confusion regarding procedures and our
subsequent changes to those procedures, Human BioSystems is hereby extending the
deadline from December 29, 2005 to January 31, 2006. This should allow
sufficient time to return any remaining Reg S shares.

You may contact our Trustee, Mr. Karsten Behrens, who is German and can answer
your questions. Mr. Behren's office phone number in Switzerland is 41 219 222
472. You may also contact our transfer agent Salli Marinov at First American
Stock Transfer in the U.S. at 602-485-1346 or by email at
salli@firstamericanstock.com if you need the Exchange Form or clarification on
the procedure to transfer the Reg S shares to First American. The procedure
calls for the faxing of the completed Exchange Form and the bank statement
showing ownership of the shares to First American Stock Transfer at 602-788-0423
(fax) and to Human BioSystems at 650-327-8658 (fax).

We are now in the process of registering the New Stock with the Securities and
Exchange Commission (SEC) so that we can begin distributing these shares to you
in exchange for the returned Reg S shares. I am hopeful that this can be done
soon.

If your bank or broker has already submitted your Reg S shares through a DTC
Participant by the original deadline of December 29, 2005 and you wish to
receive confirmation of this transaction, contact your bank or brokerage firm,
or you may contact First American Stock Transfer directly to receive a
confirmation notice.

Thank you for your investment in Human BioSystems and your patience during this
exchange process.

This Exchange Extension letter will also be submitted to Clearstream and
Euroclear for distribution so that we may reach as many Reg S Shareholders as
possible.




Very truly yours,


/s/ Harry Masuda
___________________________
 Harry Masuda
 CEO, Human BioSystems

cc: Cathryn S. Gawne, Esq.
    Mr. Karsten Behrens
    Clearstream
    Euroclear
    DTC
    First American Stock Transfer